T2I
IMMU

Turim 21 Investimentos’s Immunomedics Inc IMMU Stock Holding History

Turim 21 Investimentos’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-994
Closed -$23.5K – 31
2018
Q2 		$24K Buy
+994
New +$20K 0.01% 29

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Turim 21 Investimentos's IMMU Position: Q3 2018 in Review

Turim 21 Investimentos sold out of Immunomedics Inc (IMMU) in Q3 2018, closing a stake of 994 shares — an estimated $23.5K sold.

Turim 21 Investimentos first reported a position in IMMU in Q2 2018 and held it in 1 quarter. The position peaked at $24K in Q2 2018. 207 funds tracked by Wall St. Rank hold IMMU as of Q3 2018.

  • Turim 21 Investimentos reported no remaining Immunomedics Inc position as of Q3 2018 after selling out during the quarter.
  • Turim 21 Investimentos sold 994 Immunomedics Inc shares in Q3 2018, an estimated $23.5K.
  • Turim 21 Investimentos first reported a position in Immunomedics Inc in Q2 2018 and held it in 1 quarter.
  • Turim 21 Investimentos's Immunomedics Inc position peaked at $24K in Q2 2018.
  • 207 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2018.

Based on Turim 21 Investimentos's 13F filing for Q3 2018, filed 9 Nov 2018.